Fortis Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $266K | Hold |
1,056
| – | – | 0.12% | 104 |
|
|
2026
Q1 | $229K | Sell |
1,056
-23
| -2% | -$5.1K | 0.11% | 114 |
|
|
2025
Q4 | $247K | Buy |
1,079
+23
| +2% | +$5.24K | 0.13% | 109 |
|
|
2025
Q3 | $245K | Buy |
+1,056
| New | +$215K | 0.14% | 108 |
|
|
2025
Q2 | – | Sell |
-1,288
| Closed | -$270K | – | 118 |
|
|
2025
Q1 | $270K | Buy |
1,288
+139
| +12% | +$27K | 0.18% | 89 |
|
|
2024
Q4 | $204K | Sell |
1,149
-257
| -18% | -$47.3K | 0.13% | 104 |
|
|
2024
Q3 | $278K | Hold |
1,406
| – | – | 0.18% | 89 |
|
|
2024
Q2 | $241K | Hold |
1,406
| – | – | 0.17% | 88 |
|
|
2024
Q1 | $256K | Hold |
1,406
| – | – | 0.17% | 83 |
|
|
2023
Q4 | $218K | Hold |
1,406
| – | – | 0.16% | 82 |
|
|
2023
Q3 | $210K | Buy |
+1,406
| New | +$206K | 0.16% | 84 |
|
|
2023
Q2 | – | Sell |
-1,656
| Closed | -$264K | – | 92 |
|
|
2023
Q1 | $264K | Hold |
1,656
| – | – | 0.17% | 76 |
|
|
2022
Q4 | $268K | Hold |
1,656
| – | – | 0.2% | 73 |
|
|
2022
Q3 | $222K | Hold |
1,656
| – | – | 0.16% | 84 |
|
|
2022
Q2 | $254K | Hold |
1,656
| – | – | 0.17% | 79 |
|
|
2022
Q1 | $268K | Buy |
1,656
+656
| +66% | +$95.3K | 0.15% | 85 |
|
|
2021
Q4 | $135K | Hold |
1,000
| – | – | 0.08% | 117 |
|
|
2021
Q3 | $108K | Hold |
1,000
| – | – | 0.07% | 126 |
|
|
2021
Q2 | $113K | Hold |
1,000
| – | – | 0.07% | 129 |
|
|
2021
Q1 | $108K | Hold |
1,000
| – | – | 0.08% | 100 |
|
|
2020
Q4 | $107K | Hold |
1,000
| – | – | 0.09% | 80 |
|
|
2020
Q3 | $88K | Sell |
1,000
-1,000
| -50% | -$94.1K | 0.08% | 79 |
|
|
2020
Q2 | $196K | Hold |
2,000
| – | – | 0.19% | 55 |
|
|
2020
Q1 | $152K | Hold |
2,000
| – | – | 0.1% | 107 |
|
|
2019
Q4 | $177K | Hold |
2,000
| – | – | 0.11% | 137 |
|
|
2019
Q3 | $151K | Hold |
2,000
| – | – | 0.07% | 154 |
|
|
2019
Q2 | $145K | Hold |
2,000
| – | – | 0.07% | 152 |
|
|
2019
Q1 | $161K | Hold |
2,000
| – | – | 0.08% | 132 |
|
|
2018
Q4 | $184K | Hold |
2,000
| – | – | 0.11% | 97 |
|
|
2018
Q3 | $189K | Hold |
2,000
| – | – | 0.11% | 76 |
|
|
2018
Q2 | $185K | Hold |
2,000
| – | – | 0.11% | 77 |
|
|
2018
Q1 | $189K | Hold |
2,000
| – | – | 0.1% | 69 |
|
|
2017
Q4 | $193K | Hold |
2,000
| – | – | 0.12% | 71 |
|
|
2017
Q3 | $178K | Buy |
+2,000
| New | +$152K | 0.12% | 64 |
|
Other funds holding ABBV
Fortis Advisors's ABBV Position: Q2 2026 in Review
Fortis Advisors held its AbbVie (ABBV) position steady in Q2 2026 at 1,056 shares worth $266K. The position accounts for 0.12% of the portfolio, ranked #104.
Fortis Advisors first reported a position in ABBV in Q3 2017 and has held it in 34 quarters since. The position peaked at $278K in Q3 2024. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Fortis Advisors held 1,056 shares of AbbVie worth $266K as of Q2 2026.
- Fortis Advisors left its AbbVie share count unchanged in Q2 2026.
- AbbVie made up 0.12% of Fortis Advisors's portfolio in Q2 2026, its #104 holding.
- Fortis Advisors first reported a position in AbbVie in Q3 2017 and has held it in 34 quarters since.
- Fortis Advisors's AbbVie position peaked at $278K in Q3 2024.
- 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Fortis Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.